Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

FS 001

Next Previous
Drug Profile

FS 001

Alternative Names: FS-001; IPN-60300

Latest Information Update: 15 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Foreseen Biotechnology
  • Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 09 Oct 2025 Ipsen plans a phase I/II trial for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in October 2025 (Parenteral) (NCT07213817)
  • 11 Jul 2024 Foreseen Biotechnology in-licenses linker-payload technology from Shanghai Escugen Biotechnology, prior to July 2024
  • 11 Jul 2024 Ipsen in-licenses FS 001 from Foreseen Biotechnology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top